Euro2K, a cohort comprising 4567 2-year survivors of childhood cancer treated between 1942 and 1985 for any type of malignant neoplasm except leukemia, was established between 1990 and 1995 by exploring the medical archives of 8 cancer centers in France Background-Cardiac disease (CD) is one of the major side effects of childhood cancer therapy, but until now little has been known about the relationship between the heart radiation dose (HRD) received during childhood and the risk of CD. Methods and Results-The cohort comprised 3162 5-year survivors of childhood cancer. Chemotherapy information was collected and HRD was estimated. There were 347 CDs in 234 patients, 156 of them were rated grade ≥3. Cox and Poisson regression models were used. The cumulative incidence of any type of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) and 7·4% (95% CI, 6.2-8.9) when only the CDs of grade ≥3 were considered. In comparison with patients who received no anthracycline and either no radiotherapy or an HRD<0·1Gy, the risk was multiplied by 18·4 (95% CI, 7.1-48.0) in patients who had received anthracycline and no radiotherapy or a HRD <0.1Gy, by 60.4 (95% CI, 22.4-163.0) in those who had received no anthracycline and an HRD≥30Gy, and 61.5 (95% CI, in those who had received both anthracycline and an HRD≥30Gy. 
O ver the past 25 years, long-term survival rates following childhood cancer have improved substantially, and chronic health conditions related to cancer therapies such as second cancers [1] [2] [3] or cerebrovascular or cardiac diseases (CDs) [4] [5] [6] have become major concerns.
Clinical Perspective on p 38
CDs are one of the main causes of death among long-term survivors. 7 The role of radiotherapy and chemotherapy in long-term risk of CD has recently been investigated in several studies. 5, [8] [9] [10] [11] The initial studies were mainly conducted in cohorts of survivors of Hodgkin's lymphoma. 12, 13 In later studies, the relationship between radiation dose and CD was investigated either in a small number of survivors or over a short follow-up period. The large Childhood Cancer Survivor Study (CCSS) 5 has investigated the dose-response relationship between radiotherapy and anthracycline therapy and CD as reported by patients without validation of the diagnosis. 5 The aim of our study was to assess the dose-response relationships between treatment characteristics (radiotherapy, chemotherapy) and medically confirmed CDs in a cohort with a very long-term follow-up.
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and the United Kingdom. 14 Between 1995 and 2009 some French patients were excluded because of the detection of diagnostic errors or duplication of records. Some patients, whose medical records had not been available when the cohort was set up but were discovered during a subsequent systematic examination of the Gustave Roussy archives, were added. Clinical and histopathologic characteristics of the childhood cancer, detailed information on treatments, and followup data were abstracted from hospital clinical records by physicians. Childhood cancers were classified according to a widely accepted classification system based mainly on histology. 15 The final database includes 4649 patients. The present analysis included 3162 5-year survivors treated in France (Figure 1 ).
In accordance with French regulations, the protocol of the study has been approved by a regional committee on ethics and by the national committee protecting the confidentiality of the data (Commission Nationale de l'Informatique et des Libertés).
Data on patient outcomes, including cause of death for deceased patients, were obtained from the Center d'épidémiologie sur les causes médicales de décès (CepiDC). 16 Causes of death for the 618 deceased patients, coded according to the 9th and 10th revisions of the International Classification of Diseases (ICD-9 17 and ICD-10 18 ), were obtained from the French Death Registry. 16 Beginning on September 1, 2005, a self-report questionnaire covering a range of adverse health events was sent to the 2094 living patients who had returned a written informed consent form, and whose addresses were available through the national health insurance system. By December 31, 2012, a total of 1911 patients (75% of those still alive) had responded.
Identification and Validation of CD Data
CDs (myocardial infarction, angina, heart failure, valvular diseases, cardiac arrhythmias and conduction disorders, and pericardial disease) were identified from multiple sources: as reported by the patient in self-questionnaires, from medical records, from long-term followup of cancer survivors, from reimbursement databases, and from the national database of causes of death.
The general practitioner or the cardiologist of all patients alive who had reported at least one of the CDs of interest was invited to complete a questionnaire confirming the diagnosis, specifying the date of onset, whether our validation criteria were met, and which drug and interventional treatment was given. A copy of medical results was asked for when appropriate.
The validation of each diagnosis was based on the criteria of the European Society of Cardiology and from the Framingham and PRIME studies [19] [20] [21] (Table I in the online-only Data Supplement) . Deceased patients were considered to have had a CD if the cause of death was myocardial infarction (ICD-9: 410-412; ICD-10: I21-I25), angina pectoris (ICD-9: 413; ICD-10: I20), heart failure (ICD-9: 428; ICD-10: I50), arrhythmias and conduction disorders (ICD-9: 426-427; ICD-10: I44-I49), valvular diseases (ICD-9: 394-397, 424; ICD-10: I05-I09), or pericarditis (ICD-9: 391, 393, 420, 423; ICD-10: I30-I32).
All confirmed CDs were graded according to the Common Terminology Criteria for Adverse Events. 22 A CD was defined as grade 1 if asymptomatic, grade 2 if symptomatic but mild enough to remain untreated, and grade ≥3 if symptomatic and treated, lifethreatening, or having led to death.
Heart Radiation Dosimetry
Heart radiation dose (HRD) for all patients who had received radiotherapy (n=2178) were reconstructed. The software for the reconstitution used a simple geometric model of a child (phantom), 23 which could be adapted to the size of the patient. The location of organs and other anatomic sites of interest could be specified by using a series of points within the phantom. Dose calculations were based on measurement models. 23 More details on the dose reconstruction procedure and reliability are available in previous publications. [23] [24] [25] Copies of radiotherapy technical charts were collected for each patient. Then dose reconstructions were performed by an Institut National de la Santé et de la Recherche Médicale (INSERM) team, taking into account patient sex, age, height, weight, thickness at the level of the target volume, treatment position, type of treatment machine, type of radiation (photons or electrons), beam energy, irradiation technique, field size and shape, gantry angle, collimator angle, presence of accessories such as wedges, target-volume location, and the dose delivered to the target volume. Because dose estimates were based on individual treatment parameters, the accuracy of the dose reconstructions may depend on the completeness of the documentation available on the patient. Complete documentation, including some imaging data, was available for ≈90% of patients. Patients for whom by guest on January 5, 2016 http://circ.ahajournals.org/ Downloaded from important dose evaluation information was missing represented <5% of our study sample. In these cases, dose reconstruction was based on surrogate information derived from data from other patients treated for the same disease, in the same institution, during the same period.
For the purpose of this study, several hundred additional dose estimation points at the level of the heart were added to the phantom. In this study, HRD was defined as the median value of the heart dose distribution.
Chemotherapy
Antineoplastic drugs were classified according to their known mechanisms of action in the cell: anthracycline, alkylating agents, vinca alkaloids, epipodophyllotoxins, antimetabolites, and other drugs. A description of chemotherapy drugs and doses is presented in Table II in the online-only Data Supplement.
All patients treated with anthracycline had received a bolus infusion.
Statistical Analysis
Follow-up ran from 5 years after the diagnosis of childhood cancer until the occurrence of one of the following events: the occurrence of CD, response to the self-administered questionnaire reporting no CD, death, or last medical contact; hence, the study of the risk of a first cardiac event.
Cox proportional hazards regression model was used to evaluate the effects of the type of first cancer and of treatment on the risk of a first CD. 26 Age at first cancer plus 5 years was used as the entry time and attained age as a timescale. 27 The models were adjusted on the calendar year and age at first cancer diagnosis, and on sex.
A sensitivity analysis was performed on the subset of patients who had returned the self-report questionnaire, adjusting for the effects of tobacco consumption and body mass index.
Hazard ratios are reported here as relative risks. Estimation of relative risk (RR) was performed using SAS 9·3 (SAS Inst. Inc., Cary, NC). Dose-effect modeling was performed using Epiwin software version 1·81. A Poisson regression model was used to evaluate the dose-effect relationship for HRD and occurrence of CD. Standard radiobiological models were used to model the variation in RR. Radiation dose-response patterns were evaluated by fitting a linear model for the RR by using the formula: RR = 1 + β D, where D is the HRD in grays (Gy) and β is the excess relative risk (ERR).
The dose-response relationship appeared to be linear both with and without anthracycline. Adding an exponential or quadratic term did not improve the fit of the model (P>0.2).
Only results derived from the linear model are described in this article. Potential variations in ERR across levels of anthracycline and attained age were investigated using effect modification models (interaction).
The linear trend in effect modification by radiation dose was tested by comparing the models with and without an interaction term. Nested models were compared by using the likelihood ratio test. Twosided P values were used throughout and a result with P<0.05 was considered significant.
Role of Funder
The funding agencies had no role in the design or conduct of the study; nor in the collection, management, analysis, or interpretation of the data; nor in the preparation, review, or approval of the manuscript. All authors agreed to submit the manuscript for publication.
Results
Cardiac Diseases
The median follow-up time after diagnosis of first cancer was 26 years (25th to 75th percentile, 18-32 years) and 33% of the 5-year survivors were followed up for at least 30 years.
We observed 347 CDs in 234 survivors and 156 of them had at least one grade ≥3 CD. The most frequent types of CD were heart failure (38%), valvular disease (23%), cardiac arrhythmia (17%), pericardial disease (7%), conduction disorder (6%), myocardial infarction (6%), and angina pectoris (3%; Table III in the online-only Data Supplement).
The cumulative incidence of first diagnosis of CD at 40 years of age was 11.0% (95% confidence interval [CI], 9.5-12.7) when all grades were taken into account, and 7.4% (95% CI, 6.2-8.9) when only CDs of grade ≥3 were taken into account.
The percentage of patients with any type of CD by 40 years of age varied according to the type of first cancer, from 1.2% (95% CI, 0.2-8.3) after a central nervous system tumor to 32.6% (95% CI, 24.8-42.0) after Hodgkin disease (Table 1 ). These differences were explained by differences in treatment and were no longer significant after adjusting for use of anthracycline and HRD. The same results were obtained when restricting analysis to CDs of grade ≥3 (Table 1) . CI indicates confidence interval. *Cox model using attained age as the timescale and age at first cancer plus 5 years as the entry time, adjusted for age (in years) and calendar year of first cancer, radiation dose to the heart, and anthracycline. January 5, 2016
Chemotherapy
When the chemotherapy classes were considered individually, anthracycline alkylating agents and vinca alkaloids were associated with an increased risk of CD. When these chemotherapy classes were considered simultaneously, only the association with anthracycline remained statistically significant (RR = 3.1 for anthracycline treatment in comparison with no anthracycline treatment, 95% CI, 2.2-4.4; Table 2 ).
In comparison with patients treated without anthracycline, the risk of CD was multiplied by 4.8 (95% CI, 3.1-7.4) in High exposure to alkylating agents was also associated with a risk of CD multiplied by 1.7 (95% CI, 1.1-2.6), in comparison with no alkylating agent ( Table 2 ).
In the analysis of risk by drug combinations, only those including anthracycline (Table 2 ) affected risk of developing CD. A similar pattern of results was found when only CDs of grade ≥3 were considered.
The occurrence of heart failure started at a younger age in patients treated with anthracycline than in other patients ( Figure I in the online-only Data Supplement). This was not observed for ischemic, valvular, and pericardial diseases, arrhythmias, and conduction disorders ( Figure I in the onlineonly Data Supplement).
When age at first cancer was fitted as a dichotomous indicator variable (<10, ≥10 years), the risk of CD was nearly 4 times higher (<0.001) in patients treated with anthracycline before 10 years of age (RR, 4.0; 95%CI, 2.8-5.9) than in patients treated after (RR, 1.2; 95% CI, 0.7-2.3).
Heart Radiation Dose
The mean dose of radiation to the heart was 7.5 Gy for all patients, 17.2 Gy for patients with CD, and 19.7 Gy for patients with a CD of grade ≥3.
The 5-year survivors treated with anthracycline and a HRD>15 Gy had an increased risk of CD at a younger age than other patients (Figure 2) .
Both with and without anthracycline, patients who had received an HRD of ≥30 Gy had a risk of CD multiplied by 61.5 and 60.4, respectively, in comparison with patients who had received no radiation or a dose of radiation to the heart <0.1 Gy and no anthracycline ( Table 3 ). The findings were similar when the analysis controlled for smoking status and body mass index (data not shown). Anthracycline increases the risk of heart failure at an HRD of >15 Gy (Table IV in the online-only Data Supplement).
In patients who had received anthracycline, the excess relative risk of developing CD per Gy (ERR/Gy) was 0.07 per Gy (95% CI, 0.03-0.13) in comparison with 0.49 (95% CI, 0.26-1.3) in patients who had not received anthracycline (interaction P value <0.001); this lower slope for the effect of HRD in patients treated with anthracycline is associated with a higher baseline risk at a radiation dose of 0 leading to similar risks at high HRD with and without anthracycline.
When only CDs of grade ≥3 were analyzed or when the analysis controlled for smoking status and body mass index, then results were similar (data not shown).
In patients who had not received anthracycline, the risk of radiation-induced CD increased markedly with attained age. The ERR/Gy was 0.26 (95% CI, 0.06-0.82) up to 20 years and 0.87 (95% CI, 0.28-3.46) at >40 years of age, but there was no increase in risk with attained age in patients who had not received anthracycline (interaction between dose and anthracycline × attained age: P<0.001; Figure 3) .
No significant interaction (P>0.5) was observed between the effects of HRD and age at childhood cancer or sex.
Discussion
CD is one of the leading causes of morbidity and mortality worldwide. In recent decades, survival rates for childhood cancers have improved dramatically, although mortality remains increased beyond 5 years of follow-up. Although treatment of pediatric solid tumors has changed considerably in recent decades, the availability of very long-term follow-up data in our cohort provided an excellent opportunity to investigate the relationship between CD and both HRD and chemotherapy. Our analysis may be used to improve prediction of the longterm risk of CD associated with new therapeutic techniques.
We had previously reported the increased cardiovascular mortality in the cohort 6 ; the present study reports the risk of validated CDs. 
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This study demonstrates that a high HRD during treatment for childhood cancer is associated with a very high risk of later CD, a risk that is not markedly increased by anthracycline, although it hastens the onset of CD.
In patients who had received anthracycline, the ERR/Gy was 0.07 per Gy in comparison with 0.49 in patients who had not received anthracycline. This lower slope for the effect of HRD in patients treated with anthracycline is associated with a higher baseline risk at a radiation dose of 0 leading to similar risks at high HRD with and without anthracycline.
Another important result is that the risk of radiationinduced CD increased markedly with age, which is worrying given the young age and hopefully long life expectancy of the population studied; the median age at onset of CD was 29 years and the median age of the cohort was 31 years at the end of follow-up.
The CCSS study 5 provided a detailed analysis of the doseresponse relationships between radiation and anthracycline therapy. However, the CCSS investigators were not able to medically validate cardiac events.
The Netherlands Cancer Institute 9 cohort included 42 validated CD cases with grade ≥3 whereas, in our study, 156 such cases were included.
In addition, we analyzed systematically all and symptomatic (grade ≥3) first cardiac events, and the risks associated with HRD and anthracycline were similar for both. by guest on January 5, 2016 http://circ.ahajournals.org/ Downloaded from
The cumulative incidence of first diagnosis of all CDs was 5.0% and 11.0% at 30 and 40 years of age, respectively. When only CDs of grade ≥3 were taken into account, the incidence was 3.4% and 7.4% at 30 and 40 years of age, respectively. These proportions are close to the 30-year cumulative incidence of first CD in the Netherlands Cancer Institute study: 4.2% (95% CI, 2.8%-5.6%).
According to our study, heart failure was the most common CD after childhood cancer treatment, 5 and anthracycline had an impact only on heart failure by increasing the risk at a particularly young age; it had no impact on the other CD types.
The shorter induction period for CD in 5-year survivors treated with both anthracycline and heart radiation has been confirmed in the Netherlands Cancer Institute study. 9 As previously noted, radiation and anthracycline damage the heart through different pathophysiological mechanisms. Radiation damages the endothelium of myocardial capillaries leading to ischemia and ultimately myocardial fibrosis. Anthracycline principally damages cardiomyocytes directly, 28 resulting ultimately in diffuse myocardial fibrosis. In rabbits, the combined effect of radiation and anthracycline is additive. 29 These studies did not estimate the ERR of CDs in patients treated with or without anthracycline, so we were unable to compare our ERRs.
Darby et al 30 reported the risk of ischemic CD increasing with HRD by 7.4% per Gy in women who had received radiation therapy for breast cancer. It is difficult to compare this result with ours because only ischemic diseases were studied and because cardiac radiation exposure during breast radiation therapy was limited to a small portion of the anterior heart and was higher than in our study. A weakness of our study is the lack of information on the part of the heart that had been irradiated. The study by Darby et al 30 reported that radiation dose to the left anterior descending coronary artery did not play a role in CD risk after adjusting for average HRD. A single parameter, such as mean or median HRD as estimated in our study, is probably not sufficient to describe the distribution of HRDs during radiotherapy.
Several factors reinforce our findings. This cohort was established from 1985 to 1995. Medical and treatment data were collected extensively during this period from medical and radiological records. Although Dos_EG software was last updated in 2006, new dosimetric estimations were generated for the whole cohort by running it in batches with patient and technical data collected between 1990 and 1995, without manual intervention. Consequently, the relation between the HRD and the risk of CDs that we estimated is unlikely to be biased. In addition, the results remained stable in a sensibility analysis excluding 129 patients with dose reconstruction based on surrogate information.
Consistent with previous studies, we found that anthracycline was the main cardiotoxic chemotherapy. 31, 32 As in a previous study of CD following breast cancer treatment, 30 we found that the results did not vary after adjusting for smoking status and body mass index.
Our cohort included patients treated before 1986; further epidemiological data should be gathered from more recently treated patients because radiation therapy and chemotherapy techniques are constantly being improved.
Finally, we may have underestimated the risk because some patients (and even their medical doctors) may not be aware of occult problems unless proactively investigated, and cardiac symptoms may be misattributed to noncardiac issues (pulmonary, neurological, etc).
Conclusions
Our results have implications both for the planning of new treatments and for the follow-up of childhood cancer survivors; they ought to be taken into account for long-term monitoring of CD in this population. Surviving patients should be aware of the risk of late CD and should be counseled to avoid other cardiac risk factors.
Cardiac follow-up should be undertaken for all patients who have received heart radiation or anthracycline treatment to enable the detection of CD, which may occur at a very young age, particularly after anthracycline.
The evidence presented here points to the need for molecular epidemiological studies and, in particular, for research into the biological mechanisms underlying the association between radiation treatment and CD in the absence and presence of anthracycline therapy. The most important biological question to emerge from our study is whether the mechanisms of cardiotoxicity are the same for radiation and for anthracycline therapy. Basic and translational researches are ongoing to clarify the pathophysiological mechanisms of the late cardiac effects of these treatments with the aim of developing preventive measures. Pain with the three following characteristics: -In chest (tightness, irradiation possible in arms, neck, jaw, duration <10min) -Caused by exertion or emotion -Relieved by rest and/or by nitrates Or pain with two of these three characteristics, associated with at least one of the four following signs:
SUPPLEMENTAL MATERIAL
Supplementary
-Stenosis detected by angiography (> 50%) -Positive scintigraphy -Positive exercise testing -Modification of the resting ECG without necrosis Heart failure At least two major criteria among: paroxysmal nocturnal dyspnea or orthopnea; distended neck veins; rales; increasing heart size by X-ray; acute pulmonary edema; ventricular S3 gallop; increased venous pressure (>16 cm H2O); hepatojugular reflux; pulmonary edema, visceral congestion, cardiomegaly at autopsy; weight loss on CHF Rx: 10 lb/5 days. Or one major criterion and two minor criteria among: bilateral ankle edema; night cough; dyspnea on ordinary exertion; hepatomegaly; pleural effusion; decrease in vital capacity by one third from maximum record; tachycardia (≥ 120 beats/min); pulmonary vascular engorgement. When these Framingham criteria cannot be evaluated, at least one among: -Dyspnea -Deterioration of the parameters detected by echocardiography (ejection fraction <50% and/or shortening fraction <25% and/or alteration of wall stress (>) -Drug treatment of heart failure Valvular heart disease Echocardiography diagnosis Cardiac arrhythmia and conduction disorders ECG and/or Holter exams
Pericarditis
Chest pain for at least several hours, increasing with inspiration, or when coughing or in supine position, and decreasing with expiration, or in the sitting position, or when leaning forward. And/or pericardial friction at heart auscultation; abnormally long
